Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11274154 Dosing regimen of avelumab for the treatment of cancer

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Shaonan Wang0

Glen Ian Andrews0

Pascal Girard0

Satjit Singh Brar0

Carlo Leonel Bello0

Date of Patent

March 15, 2022

0

Patent Application Number

163397790

Date Filed

October 5, 2017

0

Patent Citations

US Patent 10487147 Anti-PD-L1 antibodies and uses thereof

0

US Patent 10323092 Cancer immunotherapy by disrupting PD-1/PD-L1 signaling

0

US Patent 10570202 Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer

0

US Patent 10004755 Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity

US Patent 10138299 Cancer immunotherapy by disrupting PD-1/PD-L1 signaling

Patent Primary Examiner

Ilia I Ouspenski

0

The present invention relates to dosing regimen of avelumab for the treatment of cancer. In particular, the invention relates to improved dosing regimen of avelumab for the treatment of cancer.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11274154 Dosing regimen of avelumab for the treatment of cancer

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool